ESPE Yearbook of Paediatric Endocrinology

Brief summary: This phase 3 double-blind, parallel-group, randomized, placebo-controlled trial over 68 weeks randomised (2:1) 201 adolescents with obesity to receive semaglutide 2.4 mg once weekly or placebo. Both groups also received lifestyle intervention. The primary endpoint was the percentage change in BMI. Treatment with semaglutide produced clinically relevant reductions in BMI and body weight, and improvements in cardiovascular risk factors, which were all significantl...

Brief Summary: For both clinicians and patients, it is of great interest to have easily-applicable predictors to forecast weight reductions achievable by lifestyle intervention (LI). This study identified 3 distinct clusters of responses to paediatric outpatient LI. Up to 2 years after LI initiation, responses ranged from ‘pronounced BMIz loss’ (in 19% of patients; median delta-BMIz: -0.61 (IQR: -0.76 to -0.49) to ‘moderate BMIz loss’ (in 45%; -0.23 (-0.33 ...

N Engl J Med 2019; 10.1056/NEJMoa1903822.DOI: 10.1056/NEJMoa1903822http://www.ncbi.nlm.nih.gov/pubmed/31034184Summary: In a double-blind, randomized, phase 3 trial, 135 overweight and obese adolescents, aged 10 to 17 years with T2DM, were randomly assigned to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo, bot...